Search Results

Eli Lilly and Co. could face the juicy prospect of a $2 billion hole in the diabetes market if the Food and Drug Administration acts on a recommendation from one of its safety scientists. David Graham is set to tell FDA advisers today to pull diabetes pill Avandia from the U.S. market, according to Bloomberg. […]

Emotions in the Seattle area are still raw months after Indianapolis-based Eli Lilly and Co. bought full ownership of Icos Corp. and promptly announced that it would wipe out most of Icos’ 700 jobs. Lilly acquired the Bothel, Wash., maker of the Cialis erectile dysfunction drug for $2.3 billion in December. The massive job loss […]

A Food and Drug Administration advisory panel has recommended approving Eli Lilly and Co.’s Evista osteoporosis drug for cutting the risk of cancer in post-menopausal women with osteoporosis and post-menopausal women at high risk for breast cancer. The non-binding recommendation follows an announcement from Lilly earlier this month that Evista reduced the risk of certain […]

Charges from two acquisitions caused second-quarter profits at Eli Lilly and Co. to slip. Excluding those expenses and other adjustments, Lilly’s profit zoomed past Wall Street’s estimates. The Indianapolis-based drugmaker earned 90 cents per share, excluding unusual items. Analysts expected 82 cents per share, according to a survey by Thomson Financial. Lilly earned 76 cents […]

Indianapolis-based Eli Lilly and Co. and other multinational companies are socking away profits in overseas tax shelters and ultimately stripping the U.S. Treasury of about $50 billion annually, according to The New York Times. Last year, Lilly paid only 6 percent of its $3.4 billion in global profits in taxes, the newspaper said. That’s a […]

Eli Lilly and Co. may have found a new use for its osteoporosis drug Evista, according to Bloomberg. The U.S. Food and Drug Administration said Evista reduced the risk of certain invasive breast cancers in post-menopausal women. However, studies from Indianapolis-based Lilly provided weaker support for Evista’s ability to help women at high risk of […]

As early as next year, Moody’s Investors Service could lower its debt rating on Eli Lilly and Co. because of the looming patent expiration of Lilly’s top-selling drug, Zyprexa. In a quarterly snapshot of the drug industry, Moody’s said it will take a hard look at any pharmaceutical company with a blockbuster drug set to […]

Eli Lilly and Co. has been ordered by the Food and Drug Administration to yank certain ads and promotions for its Reconcile drug for separation anxiety in dogs because the promotions are “misleading.” Lilly didn’t note that some dogs in trials improved because they were given behavior modification training, and did not receive just a […]